Filing summary
Entity note: The supplied filing is Sigma Labs, Inc.’s Form 10-Q for the quarter ended June 30, 2013, not a filing identified as Nexttrip, Inc. The figures below summarize the supplied filing.
Business context and reporting period
Sigma Labs develops manufacturing and materials technologies, including PrintRite3D for in-process inspection of metal additive manufacturing. It also earns revenue from consulting, principally through Sumner. The filing covers the three and six months ended June 30, 2013, compared with the same 2012 periods; balance-sheet comparisons are to December 31, 2012.
Key financial metrics
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $307,985 | $107,633 | $472,249 | $193,725 |
| Gross profit | $158,436 | $18,888 | $235,770 | $19,164 |
| Gross margin | 51.4% | 17.5% | 49.9% | 9.9% |
| Net loss | $(122,478) | $(379,911) | $(319,094) | $(634,648) |
| Operating cash flow | Not separately provided | $13,662 | $(349,507) |
At June 30, cash was $463,733, accounts receivable $153,278, current assets $634,733, current liabilities $470,395, and working capital $164,338. Total liabilities were $470,395 and total stockholders’ equity was $355,376. No borrowings or debt balance are reported. Current liabilities included $300,000 received toward a stock offering that remained pending at quarter-end. Cash increased from $150,071 at year-end, supported by $300,000 of financing proceeds and positive operating cash flow.
Material changes versus prior periods
- Six-month revenue rose 144% year over year, while gross profit increased substantially; the filing attributes revenue primarily to consulting services, not technology sales.
- The six-month net loss narrowed by about 50%, reflecting higher revenue and lower general and administrative and payroll expenses.
- Working capital declined from $315,574 at December 31, 2012 to $164,338 at June 30, 2013, despite higher cash, primarily alongside the $300,000 offering liability.
- Common shares issued increased from 429.2 million at year-end to 432.7 million at June 30; shares outstanding were 429.9 million at quarter-end.
Outlook, commentary, risks and unusual items
- Management expected to commercialize IPQA technology during fiscal 2014, but reported no technology sales at the time other than license fees payable under the Allotrope agreement.
- Management expected general and administrative, payroll and non-cash compensation expenses to increase as operations and commercialization efforts expand.
- As of August 14, management cited one active B6 Sigma consulting contract expected to generate up to $57,639 and four Sumner contracts expected to generate up to $128,352 during the remainder of 2013. Fixed-price contracts expose the company to cost-estimation and execution risk.
- Management believed available funds and expected consulting revenue would cover operating expenses through 2014, but stated that continued funding depends on consulting revenue and securities sales; additional financing may be needed, with no assurance it will be available. The filing notes recurring losses and includes a going-concern uncertainty.
- After quarter-end, the company closed a private placement on July 18, 2013, selling 120 million restricted shares at $0.01 each for $1.2 million gross proceeds. Warrants were also exercised cashlessly in July, resulting in 5,098,661 additional shares.
- A five-year exclusive marketing agreement for dental technology provides Manhattan Scientifics 30% of commercialization proceeds and Sigma Labs 70%; licenses require Sigma Labs’ approval. The company also entered an exclusive license agreement with Allotrope for specified munitions technologies.
Important facts for investors to verify
- Confirm the issuer identity: this document names Sigma Labs, Inc., whereas the request metadata names Nexttrip, Inc.
- Review the subsequent $1.2 million stock offering, its terms, and the resulting dilution, including the post-quarter warrant-related share issuance.
- Assess whether consulting contracts convert into collected revenue and whether fixed-price work is profitable.
- Track PrintRite3D commercialization progress, customer adoption, and recurring license or product revenue; the filing provides no clear quantified technology-sales outlook.
- Monitor cash needs and the going-concern risk, particularly if additional financing or profitable operations do not materialize.